American Diverisfied Holdings Corporation (ADHC) to Retain San Diego Based Bio Device Engineering Firm, Arete Bioscience, to Design GlucoGuard's Oral Diabetes Management Device
American Diversified Holdings Corporation (ADHC) has announced a partnership with Arete Biosciences to design their GlucoGuard diabetes management device. The San Diego-based bioengineering firm will develop the device following FDA Breakthrough Device directive, with guidance from GlucoGuard's advisor Dr. Stephen Weber.
The company has secured a non-dilutive funding commitment from a small cap hedge fund, which will be provided in tranches based on use of funds. Additionally, ADHC reports progress in their APP development partnership with DEXCOM for Continuous Glucose monitoring technology, utilizing artificial intelligence to predict hypoglycemia in diabetic patients.
American Diversified Holdings Corporation (ADHC) ha annunciato una collaborazione con Arete Biosciences per progettare il dispositivo di gestione del diabete GlucoGuard. L'azienda di bioingegneria con sede a San Diego svilupperà il dispositivo seguendo la direttiva FDA Breakthrough Device, con il supporto del consulente di GlucoGuard, il dott. Stephen Weber.
La società ha ottenuto un finanziamento non diluitivo da parte di un hedge fund di piccole dimensioni, che sarà erogato a tranche in base all'utilizzo dei fondi. Inoltre, ADHC segnala progressi nella partnership per lo sviluppo di un'app con DEXCOM per la tecnologia di monitoraggio continuo della glicemia, utilizzando l'intelligenza artificiale per prevedere l'ipoglicemia nei pazienti diabetici.
American Diversified Holdings Corporation (ADHC) ha anunciado una colaboración con Arete Biosciences para diseñar su dispositivo de manejo de la diabetes GlucoGuard. La empresa de bioingeniería con sede en San Diego desarrollará el dispositivo siguiendo la directiva FDA Breakthrough Device, con la orientación del asesor de GlucoGuard, el Dr. Stephen Weber.
La compañía ha asegurado un compromiso de financiación no dilutiva de un fondo de cobertura de pequeña capitalización, que se proporcionará en tramos según el uso de los fondos. Además, ADHC informa avances en su asociación para el desarrollo de una aplicación con DEXCOM para la tecnología de monitoreo continuo de glucosa, utilizando inteligencia artificial para predecir la hipoglucemia en pacientes diabéticos.
American Diversified Holdings Corporation (ADHC)가 Arete Biosciences와 협력하여 GlucoGuard 당뇨병 관리 장치를 설계한다고 발표했습니다. 샌디에이고에 본사를 둔 생명공학 회사는 FDA의 Breakthrough Device 지침에 따라 이 장치를 개발하며, GlucoGuard의 고문인 Dr. Stephen Weber의 지도를 받습니다.
회사는 소규모 헤지펀드로부터 비희석 자금 지원 약속을 확보했으며, 자금 사용에 따라 단계별로 제공될 예정입니다. 또한 ADHC는 인공 지능을 활용해 당뇨병 환자의 저혈당을 예측하는 연속 혈당 모니터링 기술을 위한 DEXCOM과의 앱 개발 파트너십에서 진전을 보고했습니다.
American Diversified Holdings Corporation (ADHC) a annoncé un partenariat avec Arete Biosciences pour concevoir leur dispositif de gestion du diabète GlucoGuard. La société de bio-ingénierie basée à San Diego développera l'appareil conformément à la directive FDA Breakthrough Device, avec les conseils du conseiller de GlucoGuard, le Dr Stephen Weber.
L'entreprise a obtenu un engagement de financement non dilutif d'un fonds spéculatif à petite capitalisation, qui sera versé par tranches en fonction de l'utilisation des fonds. De plus, ADHC rapporte des progrès dans son partenariat de développement d'application avec DEXCOM pour la technologie de surveillance continue du glucose, utilisant l'intelligence artificielle pour prédire l'hypoglycémie chez les patients diabétiques.
American Diversified Holdings Corporation (ADHC) hat eine Partnerschaft mit Arete Biosciences angekündigt, um ihr Diabetes-Management-Gerät GlucoGuard zu entwickeln. Das in San Diego ansässige Bioengineering-Unternehmen wird das Gerät gemäß der FDA Breakthrough Device-Richtlinie entwickeln, unter Anleitung von GlucoGuard-Berater Dr. Stephen Weber.
Das Unternehmen hat eine nicht verwässernde Finanzierungszusage von einem Small-Cap-Hedgefonds erhalten, die in Tranchen je nach Mittelverwendung bereitgestellt wird. Außerdem berichtet ADHC über Fortschritte in ihrer App-Entwicklungspartnerschaft mit DEXCOM für kontinuierliche Glukoseüberwachungstechnologie, die künstliche Intelligenz zur Vorhersage von Hypoglykämie bei Diabetikern nutzt.
- Secured non-dilutive funding commitment from a hedge fund for development
- Partnership with established bioengineering firm Arete Biosciences for device design
- Collaboration with DEXCOM for continuous glucose monitoring technology
- FDA Breakthrough Device designation status for GlucoGuard
- Development is still in early stages, requiring multiple approval steps
- Exact funding amount and terms not disclosed
- Timeline for FDA approval process unclear
ADHC Receives Funding Commitment from Small Cap Hedge Fund to Finance GlucoGuard Development
Del Mar, California--(Newsfile Corp. - May 19, 2025) - American Diversified Holdings Corporation (OTC Pink: ADHC) is pleased to announce the company is to retain San Diego based bio engineering firm ARETE BIOSCIENCES, Inc. to design the GlucoGuard diabetes device pursuant to the recent FDA Breakthrough Device directive.
Arete BioScience's team of scientists and biomechanical engineers have completed a review of GlucoGuard's foundational documentation including intellectual property, design schematics, and FDA application documentation. The team has devised a development protocol that will be initiated with the input and guidance of GlucoGuard's advisor Dr. Stephen Weber in order to facilitate the next step in the FDA approval process.
Additionally, ADHC has received a funding commitment from a seasoned hedge fund that specializes in financing public companies. This funding will be NON-DILUTIVE following a financing model that is not detrimental to the trading environment of ADHC stock.
This funding will be provided in one or more tranches based upon a "USE OF FUNDS" provided to the hedge fund.
"Developments are rapidly coming to together as development partners are recognizing the potential of the GlucoGuard technology. The GlucoGuard team led by Advisor Dr. Weber, and co Founder Zach Smith are now in a position fully accelerate the development," commented ADHC. "In conjunction with the device engineering, the APP Development in partnership with DEXCOM Continuous Glucose monitoring technology in rapidly progressing," concluded ADHC.
These relationships serve to build out the GlucoGuard footprint as an emerging biodevice technology providing a novel solution to the serious unmet challenge in managing HYPOGLECMIA in diabetic patients.
More news on the DEXCOM partnership progression, how GlucoGuard is utilizing Artificial Intelligence in predicting Hypoglycemia and other key issues will be publicized in the near term.
ABOUT ARETE BIOSCIENCES, Inc.
Arete BioSciences, Inc. ("Arete") is a contact service organization with expertise in the design and development of early-stage medical technologies. Arete maintains an extensive network of internal staff and collaborators with experience across device form factor exploration, rapid prototyping, and product visualization in the health space.
Arete BioScience includes a team of scientists, strategic thinkers, problem solvers, engineers, and innovators passionate about creating a positive impact on global health. Projects include the design, development, and management of molecular diagnostic systems, molecular assays, start-ups, and build-ups of several companies, and have managed product development teams across four continents in seven countries.
ABOUT DR. STEPHEN WEBER, MD
Dr. Weber is currently an Assistant Professor at the Johns Hopkins School of Medicine. He previously served as a Medical Officer and Clinical Reviewer at The US Food and Drug Administration (FDA) and practiced medicine as an Orthopedic Surgeon for over 25 years.
ABOUT GLUCOGUARD
ADHC is a medical device company developing GlucoGuard, a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of hypoglycemia "low blood sugar" during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, GlucoGuard is at the forefront of diabetes management technology.
GlucoGuard combines advanced engineering, artificial intelligence (AI), and mobile app-based monitoring to create an innovative solution for managing nocturnal Hypoglycemia. The GlucoGuard mouthpiece continuously monitors glucose levels during sleep and automatically administers glucose when hypoglycemic levels are detected. Sophisticated AI algorithms facilitate this process, ensuring effective glucose management without disturbing the patient's rest.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/252545_3686d4b01433fa71_001full.jpg
ABOUT THE DIABETES MARKET
The diabetes market is poised for substantial growth, with the U.S. market valued at
The Continuous Glucose Monitoring (CGM) sector, valued at
For more information, visit: www.GlucoGuardSleep.com.
Contact: Phone: 817-525-0057
www.GlucoGuardSleep.com
www.UniversalWellnessAI.com
John Cacchioli, CEO
American Diversified Holdings Corporation
Telephone: (212) 537-5900
Email: JC@American-Diversified.com
Social Media:
TWITTER: @ADHCManagement.
This Twitter page is the only official Twitter page for ADHC.
SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252545
FAQ
What is ADHC's GlucoGuard device and what does it do?
Who is developing ADHC's GlucoGuard device?
How is ADHC funding the GlucoGuard development?
What is the significance of ADHC's partnership with DEXCOM?
What is the current status of ADHC's GlucoGuard FDA approval?
